Indoxyl Sulfate and High-density Lipoprotein Cholesterol in Early Stages of Chronic Kidney Disease

CURRENT STATUS: POSTED

Li Wang
Zhongshan Hospital Fudan University

Corresponding Author
ORCiD: https://orcid.org/0000-0002-7073-2827

Fangfang Xiang
Zhongshan Hospital Fudan University

Jun Ji
Zhongshan Hospital Fudan University

Jianzhou Zou
Zhongshan Hospital Fudan University

Yunqin Chen
Zhongshan Hospital Fudan University

Ning Xue
Zhongshan Hospital Fudan University

Lin Zhang
Zhongshan Hospital Fudan University

Xiaotian Jiang
Zhongshan Hospital Fudan University

Xiaoqiang Ding
Zhongshan Hospital Fudan University

Xuesen Cao
Zhongshan Hospital Fudan University

DOI:
10.21203/rs.2.18545/v1
SUBJECT AREAS
Urology & Nephrology

KEYWORDS
Indoxyl sulfate, High-density lipoprotein cholesterol, Chronic kidney disease, Cardiovascular disease, Lipids
Abstract
Background: High indoxyl sulfate (IS) levels and low high-density lipoprotein cholesterol (HDL-c) levels are both risk factors of cardiovascular diseases (CVD) in chronic kidney disease (CKD) patients, the connection between which has not been clearly clarified. This study aimed to explore the relationship between IS and HDL-c levels in early stages of CKD population.
Methods: Patients of CKD stage 1-3 were enrolled in this cross-sectional study. Correlations between HDL-c and IS were investigated among various clinicopathological variables.
Results: A total of 205 CKD patients (96 men) with a mean age of 43.3 years old were included in this research. There were 96 patients (46 men) in CKD stage 1 and 109 (50 men) in CKD stage 2 or stage 3. IS levels were significantly higher in CKD 2+3 group (1.50±1.74μg/ml vs 0.94±0.66μg/ml, p=0.007), while HCL-c levels were lower (1.19±0.39mmol/L vs 1.33±0.45 mmol/L, p=0.017) compared to CKD 1 group. Among all the patients, a negative correlation was observed between IS and HDL-c levels (r=-0.244, p=0.001). IS level was an independent risk factor for low HDL-c (<1.04mmol/L) incidence even after controlling for potential confounders (OR=1.63, 95% CI: 1.11-2.39, p=0.013). IS and HDL-c were both risk factors for predicting CKD stage 3.
Conclusions: Metabolic disorder of HDL-c occurs in early CKD stages, probably attributed by increased IS level. Early management of dyslipidemia and uremic toxin retention is important for delaying disease progression and preventing cardiovascular events. Keywords: Indoxyl sulfate, High-density lipoprotein cholesterol, Chronic kidney disease, Cardiovascular disease, Lipids

Background
Chronic kidney disease (CKD) is associated with higher mortality of cardiovascular disease (CVD) [1]. Indoxyl sulfate (IS), a protein-bound uremic toxin, is one of the organic anions synthesized in the liver from indole [2]. CYP2E1 is the major isoform of P450 enzymes responsible for microsomal oxidation of indole to indoxyl [3]. As one of the most extensively studied uremic toxins, IS may predict CKD progression [4] and has been shown to be associated with CVD among hemodialysis patients [5]. Epidemiological studies have shown that high-density lipoprotein cholesterol (HDL-c) level is independently and inversely correlated with CVD [6]. Reduced kidney function is associated with
disruptions in the morphology and metabolism of lipid [7–9]. Dyslipidemia in CKD is typically characterized by high triglyceride (TG) and low HDL-c levels [10]. A recently published study revealed that lower HDL-c is associated with atherosclerosis cardiovascular disease (ASCVD) in persons with CKD [11].

High serum IS levels and low serum HDL-c levels are both risk factors of CVD in CKD patients. However, the relationship between them has not been well clarified till now especially in early stages of CKD patients. This study was designed to explore whether IS has an effect on HDL-c metabolism, the results of which may provide new perspectives on CKD lipid and uremic toxins management in early stages.

Materials And Methods

Study Population

From October 2012 to January 2014, stages of CKD1, CKD2 and CKD3 patients aged 18–70 years were enrolled from Department of Nephrology, Zhongshan Hospital, Fudan University.

Exclusion criteria included: (1) Dialysis therapy; (2) Recent usage of drugs known to influence lipid metabolism; (3) Recent usage of drugs that scavenging toxins through the intestines, such as Coated Aldehyde Oxystarch; (4) History of New York Heart Association class III/IV heart failure; (5) Acute infection; (6) Liver cirrhosis; (7) Severely elevated serum alanine aminotransferase(ALT) or aspartate aminotransferase (AST) levels (1.5 times higher than normal upper limit); (8) Malignant tumor; (9) Human immunodeficiency virus infection.

All patients provided written informed consent for participation in accordance with the Declaration of Helsinki. The study was approved by the hospital ethical review board (Zhongshan Hospital, Fudan University, Shanghai, China).

Anthropometric Measurements, Blood Sampling and Clinical Data Collection

All patients were examined and blood sampling was performed in the morning after an overnight fast of 10–12h. The date of birth, underlying kidney disease, past medical history were recorded. Height and weight (light clothes and without shoes), and seated blood pressure were determined by an experienced physician. Body mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared.
24h urine sample was collected under aseptic precautions from the day before interview.

**Biochemical Measurements**

Serum albumin, prealbumin, hemoglobin, blood urea nitrogen (BUN), serum creatinine (SCr), uric acid (UA), glycated haemoglobin (HbA1c), TG, total cholesterol (TC), HDL-c, low-density lipoprotein cholesterol (LDL-c) and high-sensitivity C-reactive protein (hsCRP) were measured using standard methods in the clinical laboratory.

Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Plasma IS concentration was detected using modified high-performance liquid chromatography (HPLC) tandem mass spectrometry method as described in our previous article [5].

**Statistical Analysis**

All variables were expressed as means±SDs, or medians (interquartile ranges).

Comparisons between the 2 groups (CKD1 vs. CKD2+3) were assessed by independent samples t tests and X²-test (for categorical variables). Pearson/Spearman analysis was used to examine the correlation between IS and lipids levels and other biochemical variables.

Values of IS quartiles were defined as follows: (1) Q1: <0.54μg/ml; (2) Q2: 0.54μg/ml–0.88μg/ml; (3) Q3: 0.88μg/ml–1.59μg/ml; (4) Q4: ≥1.59μg/ml. Difference of HDL-c levels in the four IS quartile groups was tested by One-way ANOVA.

Odds ratios of low HDL-c (HDL-c<1.04mmol/L) occurrence with increased IS level were explored through multivariate longitudinal logistic regression model, in which IS values were all Ln transferred. Factors predicting CKD stage3 were also explored through multivariate longitudinal logistic regression model.

A two-tailed p< 0.05 was considered statistically significant. For all statistical analyses, SPSS Statistics 22.0 (SPSS Inc., Chicago, IL, USA) was used.

**Results**

**Characteristics of study population**

According to eGFR levels, 205 patients were divided into 2 groups: (1) CKD1 (eGFR≥90ml/min/1.73m², n = 96); (2) CKD2+3 (30ml/min/1.73m²≤eGFR<89 ml/min/1.73m², n =
Comparisons of clinical and biochemical characteristics between the 2 groups were shown in Table 1.

Age and sex were equally matched (both with \( p > 0.05 \)). There was no significant difference of blood pressure and BMI between the study groups. Prevalence of hypertension was higher in group CKD2+3 (58.7% vs 34.4%, \( p = 0.001 \)). Compared to CKD1 group, CKD2+3 group presented higher levels of HbA1c (5.79±0.99% vs 5.54±0.87%), UA (389.62±100.69μmol/L vs 328.04±86.56μmol/L), IS (1.50±1.74μg/ml vs 0.94±0.66μg/ml) and lower levels of hemoglobin (126.16±21.29g/L vs 136.45±14.77g/L) and HDL-c (1.19±0.39mmol/L vs 1.33±0.45mmol/L) (all with \( p < 0.05 \)).

Table 1. Patients characteristics

|                      | Overall            | CKD1              | CKD2+3             | \( p \)   |
|----------------------|--------------------|-------------------|--------------------|-----------|
| Demographics         |                    |                   |                    |           |
| Age, y               | 43.27±13.80        | 41.46±13.84       | 44.87±13.66        | 0.077     |
| Sex(men/women)       | 96/109             | 46/50             | 50/59              | 0.781     |
| Anthropometric       |                    |                   |                    |           |
| Measurements         |                    |                   |                    |           |
| Systolic BP, mmHg    | 131.48±17.36       | 128.92±13.87      | 133.73±19.73       | 0.1       |
| Diastolic BP, mmHg   | 82.87±11.48        | 81.48±10.19       | 84.09±12.43        | 0.06      |
| BMI, kg/m²           | 24.24±3.69         | 24.23±3.41        | 24.26±3.93         | 0.65      |
| Underlying kidney    |                    |                   |                    |           |
| disease(n, %)        |                    |                   |                    |           |
| Glomerular disease   | 164 (80.0%)        | 84 (87.5%)        | 80 (73.4%)         |           |
| Diabetic nephropathy | 16 (7.8%)          | 3 (3.1%)          | 13 (11.9%)         |           |
| Hypertensive nephropathy | 7 (3.4%)      | 2 (2.1%)          | 5 (4.6%)           |           |
| Polycystic kidney    | 10 (0.5%)          | 1 (0.1%)          | 0                  |           |
| disease(n, %)        | 10 (0.5%)          | 0                 | 1 (0.9%)           |           |
| Unknown              | 16 (7.8%)          | 6 (6.3%)          | 10 (9.2%)          |           |
| Comorbidity(n, %)    |                    |                   |                    |           |
| Hypertension         | 97 (47.3%)         | 33 (34.4%)        | 64 (58.7%)         | 0.61      |
| Diabetes             | 29 (14.1%)         | 9 (9.4%)          | 20 (18.3%)         |           |
| Gout                 | 6 (2.9%)           | 2 (2.1%)          | 4 (3.7%)           |           |
| CVD                  | 7 (3.4%)           | 1 (1.0%)          | 6 (5.5%)           | 0.1       |
| Laboratory Tests     |                    |                   |                    |           |
| Hemoglobin, g/L      | 131.00±19.17       | 136.45±14.77      | 126.16±21.29       | 0.07      |
| HbA1c, %             | 5.67±0.94          | 5.54±0.87         | 5.79±0.99          | 0.06      |
| Albumin, g/L         | 33.72±8.52         | 33.84±8.68        | 33.61±8.43         | 0.82      |
| pre-Albumin, g/L     | 0.29±0.07          | 0.29±0.06         | 0.29±0.07          | 0.6       |
| BUN, mmol/L          | 5.96±2.76          | 4.60±1.28         | 7.17±3.13          | 0.02      |
| Scr, μmol/L          | 80.50 (64.0-108.8) | 64.00 (55.5-76.5) | 107.00 (85.3-130.3)| 0.04      |
| UA, μmol/L           | 360.64±99.00       | 328.04±86.56      | 389.62±100.69      | 0.06      |
| eGFR, ml/min/1.73m²  | 84.59±26.20        | 107.88±11.32      | 64.30±16.92        | 0.01      |
| Urine protein, g/d   | 1.38 (0.74-2.81)   | 1.23 (0.69-2.67)  | 1.71 (0.95-3.16)   | 0.00      |
| IS, μg/ml            | 1.24±1.37          | 0.94±0.66         | 1.50±1.74          | 0.06      |
| TC, mmol/L           | 5.56±2.00          | 5.62±2.04         | 5.52±1.97          | 0.1       |
| TG, mmol/L           | 1.77 (1.25-2.67)   | 1.72 (1.19-2.53)  | 1.91 (1.30-2.78)   | 0.5       |
| HDL-c, mmol/L        | 1.25±0.42          | 1.33±0.45         | 1.19±0.39          | 0.06      |
| LDL-c, mmol/L        | 3.36±1.70          | 3.33±1.71         | 3.37±1.69          | 0.06      |
| hsCRP, mg/L          | 1.20 (0.43-2.38)   | 1.00 (0.48-2.20)  | 1.40 (0.40-2.63)   | 0.1       |

Continuous data expressed as mean±standard deviation or median [interquartile range]; Categorical data expressed as count (percentage).

\( p \) value: CKD2+3 group vs CKD1 group
CKD, chronic kidney disease; BP, blood pressure; BMI, body mass index; HbA1c, glycated haemoglobin; BUN, blood urea nitrogen; Scr, serum creatinine; UA, uric acid; eGFR, estimated glomerular filtration rate; IS, indoxyl sulfate; TC, total cholesterol; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein.

The association between IS and HDL-c as well as other variables

As shown in table 2, serum IS levels were positively correlated with systolic BP, diastolic BP, hypertension history, CVD history, levels of albumin, BUN, Scr and hsCRP and negatively correlated with eGFR, hemoglobin, HDL-c and urine protein levels (all with p<0.05).

The subjects were then divided into four groups according to the quartile values of IS (Q1: IS<P25, Q2: P25≤IS<P50, Q3: P50≤IS<P75, Q4: IS≥P75). Figure 1 showed that as IS levels increased, HDL-c levels decreased from group to group. Serum HDL-c level in each group was 1.40±0.48mmol/L, 1.26±0.42mmol/L, 1.23±0.37mmol/L, 1.13±0.39mmol/L respectively (p for trend = 0.014).

**Table 2. Correlation between Serum IS and HDL-c as well as other variables**

| Variables          | r     | p value |
|--------------------|-------|---------|
| eGFR               | -0.245| 0.000   |
| Systolic BP        | 0.221 | 0.001   |
| Diastolic BP       | 0.143 | 0.040   |
| Hypertension History | 0.216 | 0.002   |
| CVD History        | 0.230 | 0.001   |
| Hemoglobin         | -0.157| 0.025   |
| Albumin            | 0.280 | 0.000   |
| BUN                | 0.242 | 0.000   |
| Scr                | 0.222 | 0.001   |
| HDL-c              | -0.244| 0.001   |
| hsCRP              | 0.168 | 0.019   |
| Urine protein      | -0.254| 0.000   |

IS, indoxyl sulfate; HDL-c, high-density lipoprotein cholesterol; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; BP, blood pressure; BUN, blood urea nitrogen; Scr, serum creatinine; hsCRP, high-sensitivity C-reactive protein.

Impact of IS levels on risk of low HDL-c levels incidence

Table 3 lists the risk of low HDL-c levels (defined as HDL-c<1.04mmol/L) incidence as IS levels increased [OR = 1.56, 95%CI (1.07-2.27), p = 0.018]. After adjustment for medical history of hypertension, diabetes, gout and CVD, age, sex, Systolic BP, Diastolic BP and BMI, IS showed an odds
ratio of 1.55 [95%CI (1.05–2.30), p = 0.028]. After further adjustment for hemoglobin, HbA1c, albumin, hsCRP, eGFR, BUN, Scr, UA and 24h urine protein, IS still showed a significant OR of 1.57[95%CI (1.02–2.41), p = 0.039].

Table 3. Logistic regression of low HDL-c incidence with IS levels increment

| Model   | OR (95%CI)       | p value |
|---------|------------------|---------|
| Model 1 | 1.56 (1.07-2.27) | 0.018   |
| Model 2 | 1.55 (1.05-2.30) | 0.028   |
| Model 3 | 1.71 (1.13-2.59) | 0.010   |
| Model 4 | 1.57 (1.02-2.41) | 0.039   |

Model 1. Crude;
Model 2. Adjusted for hypertension history, diabetes history, gout history and CVD history, age, sex, Systolic BP, Diastolic BP and BMI;
Model 3. Model 2 further adjusted for hemoglobin, HbA1c, albumin and hsCRP;
Model 4. Model 3 further adjusted for eGFR, BUN, Scr, UA and 24h urine protein.

Risk factors predicting for CKD stage 3
Table 4 shows that HDL-c [OR:0.15, 95%CI(0.04–0.57)], IS[OR:1.67,95%CI(1.06–2.63)], systolic BP [OR:1.04 (1.01–1.06)], hemoglobin [OR:0.98 (0.95–1.00)] and urine protein [OR:1.23 (1.08–1.40)] levels were risk factors predicting for CKD stage 3.

Table 4. Risk factors predicting for CKD stage 3

| variables   | OR(95%CI)       | p value |
|-------------|-----------------|---------|
| HDL-c       | 0.15 (0.04-0.57) | 0.006   |
| IS          | 1.67 (1.06-2.63) | 0.027   |
| Systolic BP | 1.04 (1.01-1.06) | 0.003   |
| Hemoglobin  | 0.98 (0.95-1.00) | 0.004   |
| Urine protein | 1.23 (1.08-1.40) | 0.002   |

Adjusted for medical history of primary hypertension, diabetes, gout and CVD, sex, age, BMI, diastolic BP, HbA1c, albumin, pre-albumin, TG, TC, LDL-c and hsCRP

CKD, chronic kidney disease; HDL-c, high-density lipoprotein cholesterol; IS, indoxyl sulfate; BP, blood pressure;

Discussion
CKD is correlated with an increased risk of CVD as disease progresses[12,13]. Patients underlying dialysis therapy have an extremely high risk of cardiovascular events[14]. Actually, relationship between CKD and CVD is present even under minor renal injury. However, most studies have focused
on CVD risks mostly when eGFR is lower than 60 ml/min/1.73 m²[12–13,15]. In all relevant studies published to date, CVD is the predominant cause of increased mortality, accounting for over 50% of all deaths[12–14,16].

In general population, every 1mmol/L (40mg/dl) elevation in LDL-c level may result in an increased risk of CVD by 40% [17–18]. While in CKD patients, levels of residual renal function and proteinuria as well as comorbidities (especially type 2 diabetes) and treatment can all affect lipid metabolism [19,20]. However, the relationship between lipid profiles and CVD risks in CKD patients remains uncertain. In dialysis patients, serum LDL-c level has a negative association with all-cause mortality [21,22], the phenomenon of which is called ‘reverse epidemiology’. Low serum HDL-c levels are common among patients with CKD and ESRD [23–25]. Archna Bajaj et al. [11] recently reported that HDL-c was associated with increased risk for ASCVD beyond LDL-c among individuals with CKD. Atheroprotective functions of HDL include anti-thrombotic activities [26] and endothelium regenerative capabilities [27,28], anti-inflammatory and anti-oxidative properties [29,30]. Innumerable studies have revealed that HDL metabolism is complex and involving multiple pathways. The process of HDL biogenesis is mediated primarily by the liver. ApoA-1 is the major lipoprotein on HDL which stimulates cholesterol efflux through ATP-binding cassette (ABC) transporters. The movement of cholesterol from peripheral tissues to the liver for clearance is termed reverse cholesterol transport (RCT), a pathway that represents a key atheroprotective function of HDL. Defective maturation of HDL particles, impaired Apo-A1-mediated cholesterol efflux, and limited RCT have been revealed in CKD patients [31].

As one of the most extensively studied protein-bound uremic toxins, IS may be associated with CVD and mortality in CKD patients. The process of IS biogenesis is mediated mainly in the liver [32–36]. More and more attention has been focused on the relationship between IS levels and CVD incidence among CKD population in recent years[37–41]. Taki et al. [42] found that high serum IS level was significantly correlated with incidence of atherosclerosis. Cao et al.[5] from our group reported that high serum IS was associated with higher risk of first failure event in patients on hemodialysis.

Based on the mechanisms and clinical results above, we conducted this research targeting on the
potential relationship between IS and HDL-c in early CKD stage. Besides the negative correlation, IS was an independent risk factor of low HDL-c incidence. Even after adjusting related conventional factors such as age, sex, BMI, history of diabetes, history of primary hypertension, history of coronary heart disease, blood pressure and so on, the OR value remained statistically significant as we expected. Moreover, high serum IS levels and low serum HDL-c levels as well as systolic BP, hemoglobin and urine protein were risk factors predicting for CKD stage 3.

However, there were several limitations in this study. Firstly, the sample size was relatively small as a cross-sectional research. Secondly, the tested lipid contents (only TC, TG, HDL-c and LDL-c included) were not adequate to make omni-directional exploration of the relationship between lipid metabolism and IS in patients with CKD.

Conclusion
In conclusion, our data revealed that low HDL-c level occurs in early stages of CKD, which may be resulted from negative effect of serum IS on HDL-c biogenesis. Detailed mechanisms need to be explored by further basic researches. Aiming at slowing down CKD progression and reducing CVD risks, attentions should be paid to lipid and uremic toxin management from the very early stages.

Declarations

**Ethics approval and consent to participate**

The study protocol complied with the ethical principles of the Declaration of Helsinki and received full approval from the institutional review boards of Shanghai Fudan University Zhongshan Hospital (no.B2017-076R). All patients provided written informed consent.

**Consent to publish**

Not applicable, as it does not contain an individual person’s data.

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding authors on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.
Funding

This work was supported by the Youth Science and Technology Commission of Shanghai Zhongshan Hospital (2018ZSQN08).

Authors’ contributions

LW and FFX wrote the paper. JJ, JZZ and YQC designed the study. NX collected the data. LZ and XTJ did statistical analysis. XQD revised the manuscript. XSC interpreted the study. All authors have read and approved the final manuscript.

Acknowledgments

None.

References

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.

2. Bueschkens DH, Stiles ME: Escherichia coli variants for gas and indole production at elevated incubation temperatures. Appl Environ Microbiol48: 601–605, 1984

3. Banoglu E, Jha GG, King RS: Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur J Drug Metab Pharmacokinet26: 235–240, 2001

4. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS: p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant26: 938–947, 2011

5. Xue-Sen Cao, Jun Chen, Jian-Zhou Zou, et al. Association of Indoxyl Sulfate with Heart Failure among Patients on Hemodialysis. Clin J Am Soc Nephrol. 2015 Jan 7;10(1):111-9.

6. C.G. Santos-Gallego, J.J. Badimon, R.S. Rosenson, Beginning to understand highdensity lipoproteins, Endocrinol Metab. Clin. N. Am. 43 (2014) 913-947.

7. Reiss AB, Voloshyna I, De Leon J, Miyawaki N, Mattana J. Cholesterol metabolism in
8. Florens N, Calzada C, Lyasko E, Juillard L, Soulage CO. Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins. Toxins (Basel). 2016;8(12):E376.

9. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52.

10. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease: implications for the patho physiology of atherosclerosis. J Atheroscler Thromb. 2013;20(2):123-133.

11. Archna Bajaj, Dawei Xie, Esteban Cedillo-Couvert, et al. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. Am J Kidney Dis. 2019 Jun;73(6):827-836. 12. Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296-1305 (2004). 13. Matsushita, K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073-2081 (2010).

12. Steenkamp, R., Rao, A. & Roderick, P. UK Renal Registry 17th annual report: chapter 5 survival and cause of death in UK adult patients on renal replacement therapy in 2013: national and centre-specific analyses. Nephron129(Suppl. 1), 99-129 (2015).

13. Vanholder, R. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 20, 1048-1056 (2005).

14. United States Renal Data System. 2015 USRDS Annual Data Report volume 2: ESRD in the United States. 17. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB (1980) Prevalence of coronary heart disease in the Framingham Offspring
Study: role of lipoprotein cholesterols. Am J Cardiol 46:649–654

15. Emerging Risk Factors Collaboration et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009) 19.Hager, M. R., Narla, A. D. & Tannock, L. R. Dyslipidemia in patients with chronic kidney disease. Rev. Endocr. Metab. Disord. 18, 29–40 (2017). 20.Zheng-Lin, B. & Ortiz, A. Lipid management in chronic kidney disease: systematic review of PCSK9 targeting. Drugs 78, 215–229 (2018).

16. Lowrie, E. G. & Lew, N. L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 15, 458–482 (1990).

17. Baigent, C., Landray, M. J. & Wheeler, D. C. Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Semin. Dial. 20, 498–503 (2007).

18. Lo, J. C., Go, A. S., Chandra, M., Fan, D. & Kaysen, G. A. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am. J. Kidney Dis. 50, 552–558 (2007).

19. Ganda, A. et al. Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytectosis and atherosclerosis. Circulation 127, 988–996 (2013).

20. Anderson, J. L. et al. High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport. Sci. Rep. 7, 41481 (2017) 26.Mineo C, Deguchi H, Grifn JH, Shaul PW (2006) Endothelial and antithrombotic actions of HDL. Circ Res. 27.Besler C, Heinrich K, Rohrer L, et al. Landmesser U (2011) Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Investig.
28. Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Lüscher TF, Noll G (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399-1402. 29. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM (2004) Antiinflammatory properties of HDL. Circ Res. 30. Navab M, Yu R, Gharavi N, Huang W, Ezra N, Lotfzadeh A, Anantharamaiah GM, Alipour N, van Lenten BJ, Reddy ST, Marelli D (2007) High-density lipoprotein: antioxidant and antiinflammatory properties. Curr Atheroscler Rep 9:244-248 31. Moradi H, Vaziri ND. Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Front Biosci. 2018;23:146-161 32. Meyer TW, Walther JL, Pagtalunan ME, Martinez AW, Torkamani A, Fong PD, et al. The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int.2005 Aug;68(2):867-77.

21. Bueschkens DH, Stiles ME. Escherichia coli variants for gas and indole production at elevated incubation temperatures. Appl Environ Microbiol. 1984 Sep;48(3):601-5.

22. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr. 2010 Sep;20(5 Suppl):S2-6.

23. Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, Schepers E, et al. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant. 2011 May; 26(5):1464-7.

24. Banoglu E, Jha GG, King RS. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):235-40 37. Lin CJ, Liu HL, Pan CF, Chuang CK, Jayakumar T, Wang TJ, Chen HH, Wu CJ: Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 43: 451-456, 2012

25. Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T: Indoxyl sulphate promotes aortic
calcification with expression of osteoblast-specific proteins in hypertensive rats.

Nephrol Dial Transplant 23:1892-1901, 2008

26. Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T: Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant 24: 2051-2058, 2009

27. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H: Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 31: 1771-1779, 2010

28. Yisireyili M, Shimizu H, Saito S, Enomoto A, Nishijima F, Niwa T: Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci 92: 1180-1185, 2013

29. Taki K, Tsuruta Y, Niwa T: Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 27: 30-35, 2007

Figures
Figure 1

Trend of HDL-c levels in the four IS quartiles. * vs quartile 1, p<0.05.